Expertise in
16
conditions

Dr. Shumei M. Kato

Oncology
UCSD Heath Care
3855 Health Sciences Dr, 
La Jolla, CA 
Offers Telehealth
Expertise in
16
conditions
UCSD Heath Care
3855 Health Sciences Dr, 
La Jolla, CA 

Overview

Shumei Kato is an Oncologist practicing medicine in La Jolla, California.

Dr. Kato is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Ovarian Cancer, Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 192 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in TX

Hospital Affiliations

Uc San Diego Health Hillcrest - Hillcrest Med Ctr
Eisenhower Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UCSD Heath Care
3855 Health Sciences Dr, La Jolla, CA 92093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug, Procedure
Study Drugs: Cediranib Maleate, Olaparib
Study Phase: Phase 2
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma
A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma
Enrollment Status: Terminated
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 1
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Enrollment Status: Unknown
Publish Date: May 21, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Panitumumab, Regorafenib, Trifluridine, Tipiracil
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

192 Total Publications

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.
Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.
Journal: Hematology/oncology clinics of North America
Published: September 02, 2026
Similar Doctors
Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Ucsd Health Moores Cancer Center

3855 Health Sciences Dr, 
La Jolla, CA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lyudmila Bazhenova is an Oncologist practicing medicine in La Jolla, California. Dr. Bazhenova is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Lung Adenocarcinoma.

Expertise in
24
conditions
Dr. James I. Geller
Hematology | Oncology
Expertise in
24
conditions
Dr. James I. Geller
Hematology | Oncology
Referral may be required

Rady Children's Hospital San Diego

3020 Childrens Way, 
San Diego, CA 
 (7.0 miles away)
858-966-5811
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Geller is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Geller is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Wilms Tumor, Hepatoblastoma, Renal Cell Carcinoma (RCC), Nephrectomy, and Bone Marrow Aspiration. Dr. Geller is currently accepting new patients.

Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

City Of Hope Orange County Lennar Foundation Cancer Center

Irvine, CA 
 (61.9 miles away)
844-975-4048
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tanya Siddiqi is an Oncologist practicing medicine in Irvine, California. Dr. Siddiqi is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Frequently Asked Questions about Dr. Shumei M. Kato

How do I make an appointment with Dr. Shumei M. Kato?

You can book an appointment with Dr. Shumei M. Kato by calling their office at 858-822-2372. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shumei M. Kato a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shumei M. Kato is classified as an Advanced expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shumei M. Kato specialize in?

While Dr. Shumei M. Kato is a Oncology, they have specific expertise in Pancreatic Cancer, Ovarian Cancer, and Cholangiocarcinoma (Bile Duct Cancer). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Shumei M. Kato participate in research or clinical trials?

Yes. Dr. Shumei M. Kato has published 192 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Shumei M. Kato's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Shumei M. Kato accept my insurance?

Dr. Shumei M. Kato accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 858-822-2372 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kato's expertise for a condition
ConditionClose
      View All 16 Advanced Conditions
      View All 63 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile